Close menu

July 26th, 2021 | 13:55 CEST

BioNTech, Cardiol Therapeutics, CureVac - What is next?

  • Biotechnology
Photo credits:

Are you smiling or shaking your head? Both are easily understandable reactions that investors might have in light of the latest statements from the Deutsches Aktien Institut (DAI). The DAI calls for better conditions for IPOs of growth companies to prevent such companies from migrating to foreign stock exchanges, as happened with BioNTech, among others. "Especially companies with specialized business models and high financing needs are dependent on foreign investors," explained Uta-Bettina von Altenbockum. However, this is not a new phenomenon either. Other countries have been creating better framework conditions for corporations and better tax incentives for investors for a long time. Own goal. What opportunities are there?

time to read: 3 minutes | Author: Carsten Mainitz

Table of contents:

    David Elsley, CEO, Cardiol Therapeutics Inc.
    "[...] As a company dedicated to developing treatments for rare heart diseases, we see this as an opportune moment to contribute to the fight against heart disease and make meaningful strides in improving heart health worldwide. [...]" David Elsley, CEO, Cardiol Therapeutics Inc.

    Full interview


    BIONTECH SE - New all-time high

    The BioNTech share recently reached a new all-time high. The announcement by the US to buy another 200 million doses of the Corona vaccine from manufacturers BioNTech and Pfizer triggered the share price surge. According to the announcement, the US government is preparing for the vaccination of younger children and booster shots for adults. Pfizer said just over half of the doses would be delivered by the end of the year and the rest by April 2022. That brings the total orders to 500 million units.

    The potential vaccination of children and adolescents and booster shots will continue to keep vaccine manufacturers' coffers ringing in the months ahead. In addition, there is a high probability that with the emergence of more and more new covid variants, vaccinations will be with us for a long time to come. The European Medicines Agency (EMA) recently voted to approve a second Corona vaccine for children and adolescents. As a result, after the vaccine from BioNTech, the preparation from Moderna could now also be used. The EU Commission still has to approve the approval, but this is considered a formality.

    With a share price of around USD 282, BioNTech is currently valued at USD 58 billion. We assume that analysts will soon further increase the price targets for the shares; according to the prevailing opinion, the title is now exhausted. However, the latest developments and the resulting potential are probably not yet priced into the investment judgments. Looking at some experts' estimates, which assume earnings this year and next year in the order of USD 7 billion each, the stock is moderately valued with a P/E ratio of 8 to 9. Of course, the question is how sustainable the profits generated are. The bottom line is that the stock offers a good risk-reward ratio.

    CARDIOL THERAPEUTICS INC - Change in the Board of Directors

    Cardiol Therapeutics is breaking new ground in the therapy of inflammatory heart diseases. The Canadians are relying on cannabidiol (CBD) for therapeutic trials. A body of scientific evidence exists that cites the use of cannabidiol as beneficial as an anti-inflammatory agent.

    The Company's lead product, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is currently being evaluated in a Phase II/III outcomes study in hospitalized patients who tested positive for the Covid-19 virus. This potential pivotal study is designed to assess the efficacy and safety of CardiolRx as a cardioprotective therapeutic to reduce mortality and major cardiovascular events in Covid-19 patients with pre-existing cardiovascular disease or risk factors for cardiovascular disease. The study is also to evaluate the impact of CardiolRx on key markers of inflammatory heart disease.

    Due to age, the Company recently announced a change within the board. Dr. Guillermo Torre-Amione has now been appointed as the new Chairman. Dr. Torre-Amione has served as an independent director of Cardiol since August 2018 and now takes over from Dr. Eldon Smith, who has held the role of Chairman since Cardiol's inception and is now retiring. Dr. Guillermo Torre-Amione is a board-certified specialist in cardiovascular disease and advanced heart failure/transplant cardiology.

    Cardiol filed for listing on NASDAQ in March 2021. Inclusion in the US index is expected to result in a significant valuation boost for the stock. To further develop the Company, the Canadians raised more than CAD 50 million on the capital market in the last 12 months. Currently, a price of CAD 2.72 is being called for the shares, which means that the Company is valued at just under CAD 120 million. If the analysts at GBC are to be believed, the share has an upside potential of up to CAD 15.77!

    CUREVAC NV - What does the future hold?

    Opportunity and risk are two sides of the same coin. While Mainz-based BioNTech and partner Pfizer are writing a breathtaking success story, the Tübingen-based vaccine developer CureVac is on the downside. Some time ago, the Süddeutsche reported that the vaccine's effectiveness was only around 48%. As a result, the German government announced that the CureVac vaccine would no longer be included in the current campaign. Unsurprisingly, Curevac's share price plummeted as a result and has not recovered significantly to date. At a current share price of EUR 46, the Company is valued at around EUR 8 billion. The market will certainly take a while to price in the changed situation. Should the Company fail to launch the vaccine, the current valuation is far too high.

    No opportunity without risk. Investors should keep this in mind, especially with biotech stocks. Biontech certainly offers the best risk-reward ratio. In the case of Cardiol, a reassessment should begin in the event of success. In our opinion, the risks outweigh the rewards for CureVac.

    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.

    Der Autor

    Carsten Mainitz

    The native Rhineland-Palatinate has been a passionate market participant for more than 25 years. After studying business administration in Mannheim, he worked as a journalist, in equity sales and many years in equity research.

    About the author

    Related comments:

    Commented by Juliane Zielonka on April 12th, 2024 | 07:00 CEST

    AI in healthcare with Evotec, Defence Therapeutics, Bayer: Revolutionary advances and medical breakthroughs

    • Biotechnology
    • Pharma
    • AI

    Artificial intelligence (AI) is gaining momentum in the healthcare sector. AI-based systems can use medical databases to save valuable time in research, enabling companies like Defence Therapeutics to go to market faster than others. In oncology research, the Canadian company has just achieved a breakthrough that gives hope to many cancer patients. AI-assisted diagnoses allow diseases to be detected earlier and treated more effectively, leading to improved quality of life for patients. Precision medicine in strong partnership networks is Evotec's focus. The share is particularly popular with hedge fund managers. Analyzing medical images and data in real-time and detecting even the smallest deviations or anomalies is the top priority for Bayer AG in collaboration with Google Cloud. Which companies are convincing investors the most?


    Commented by Fabian Lorenz on April 10th, 2024 | 07:00 CEST

    BASF and Cardiol Therapeutics recommended to buy! TUI share with momentum!

    • Biotechnology
    • Cancer
    • travel
    • chemicals

    BASF shares have gained over 30% within six months. But is the rally in BASF shares slowly running out of steam? The fact that the share did not rise sharply yesterday despite a significant price target increase suggests this is the case. Many experts see little potential for further price increases. The situation is different for the biotech company Cardiol Therapeutics. The analysts at Canaccord believe that the shares of the specialist in cardiovascular diseases could perform by around 200%. Financing is secured until 2026, and important study data is due in the current quarter. The TUI share has been on a roll for several months now. Will the share continue to rise with the increase in temperatures? Management is certainly optimistic about the future.


    Commented by André Will-Laudien on April 10th, 2024 | 06:45 CEST

    Attention: Biotech takeovers, after MorphoSys, now Bayer, Vidac Pharma, BioNTech and Pfizer are on the radar

    • Pharma
    • Biotechnology
    • Innovations

    Since the onset of the COVID-19 pandemic, there has been little movement in the biotech sector. However, after a challenging year in 2023, the sector was at least able to start the new year on a solid footing. The surprising takeover of MorphoSys recently got hearts beating again, as Novartis put a whopping EUR 2.7 billion on the table for the cancer specialist from Munich. Only months before, MorphoSys had been traded on the stock exchange at just EUR 700 million. The special market situation in this case was also characterized by the high short ratio, which led to an exorbitant rise in the share price of almost 400% in the final phase. Speculative investors are now keeping a wary eye on potential takeover candidates as the sector is once again attracting considerable attention. We are taking a closer look and searching for the next pearl.